| Recruitment status | Open public recruiting |
| Unique ID issued by UMIN | UMIN000032186 |
| Receipt No. | R000036662 |
| Official scientific title of the study | Assessing Diagnostic Value of Non-invasive FFRCT in Coronary CarE |
| Date of disclosure of the study information | 2018/04/16 |
| Last modified on | 2018/04/10 (Ver. 2) |
| Basic information | ||||
| Official scientific title of the study | Assessing Diagnostic Value of Non-invasive FFRCT in Coronary CarE | |||
| Title of the study (Brief title) | HeartFlow ADVANCE Registry | |||
| Region |
|
|||
| Condition | |||
| Condition | Coronary Artery Diseases | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | The objective of the HeartFlow ADVANCE Registry is to evaluate utility, clinical outcomes, and resource utilization of FFRCT-guided evaluation in clinically stable, symptomatic patients with coronary artery disease (CAD), in order to further inform patients, health care providers, and other stakeholders about which technologies are most effective and efficient in the diagnosis and management of CAD. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | The primary endpoint of the ADVANCE Registry is the reclassification rate between the coronary management plan based on the review of the cCTA compared to the management plan based on FFRCT when obtained, as assessed by an independent review committee. |
| Key secondary outcomes | |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. Provide written informed consent
2. Clinically stable, symptomatic patients who undergo cCTA and are diagnosed with CAD and meet eligibility criteria for FFRCT. |
|||
| Key exclusion criteria | 1. cCTA showing no CAD
2. Uninterpretable cCTA by site assessment, in which severe artifacts prevent angiographic evaluation 3. Any active, serious, life-threatening disease with a life expectancy of less than 1 year 4. Inability to comply with follow-up requirements |
|||
| Target sample size | 7500 | |||
| Research contact person | |
| Name of lead principal investigator | Takashi Akasaka |
| Organization | Wakayama Medical University Hospital |
| Division name | Cardiovascular Medicine |
| Address | Kimiidera 811-1, Wakayama, Wakayama |
| TEL | 073-447-2300 |
| akasat@wakayama-med.ac.jp | |
| Public contact | |
| Name of contact person | Reiko Masui |
| Organization | HeartFlow Japan |
| Division name | Clinical Affairs |
| Address | Nishihimbashi 1-18-6, 13F, Minato, Tokyo |
| TEL | 03-3539-3730 |
| Homepage URL | |
| rmasui@heartflow.com | |
| Sponsor | |
| Institute | Wakayama Medical University Hospital |
| Institute | |
| Department | |
| Funding Source | |
| Organization | HeartFlow Inc |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Open public recruiting | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | The enrollment requires screening and informed consent. For the enrolled subjects, 4 follow up will be made, at 90 days, 180 days, 1 year and 3 year. The follow up can be made either phone or office visit. |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000036662 |